Sarepta Therapeutics Pauses Duchenne Gene Therapy Shipments Amid Safety Concerns
TL;DR Summary
Sarepta Therapeutics has unexpectedly decided to pause all shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, following a request from the FDA, reversing its initial rejection of the agency's directive.
- In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy statnews.com
- Sarepta to pause gene therapy Elevidys shipments in U.S. CNBC
- The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear statnews.com
- Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. Sarepta Therapeutics
- Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
90%
307 → 31 words
Want the full story? Read the original article
Read on statnews.com